Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Monk

Showing results (291-300 of 738) with videos related to

Pageof 74
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancerGiorgio Bogani, Robert L Coleman, Ignace Vergote, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2008
Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success?John K Chan, Stefanie M Ueda, Valerie E Sugiyama, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 15, 2023
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancerGiorgio Bogani, Robert L Coleman, Ignace Vergote, et al.
Obstetrics and Gynecology|December 7, 2002
A stiff bristled, spiral-shaped ectocervical brush: a device for transepithelial tissue biopsyBradley J Monk, Michael Cogan, Juan C Felix, et al.
Journal of Pain and Symptom Management|May 18, 2010
A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group studyVivian E von Gruenigen, Helen Q Huang, Karen M Gil, et al.
Gynecologic Oncology|December 14, 2004
Role of pegylated liposomal doxorubicin in ovarian cancerJ Tate Thigpen, Carol A Aghajanian, David S Alberts, et al.
Gynecologic Oncology|October 13, 2018
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group studyBradley J Monk, James T Kauderer, Katherine M Moxley, et al.
Gynecologic Oncology|December 27, 2008
Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group studyLeslie M Randall, Bradley J Monk, Kathleen M Darcy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group studyKoen De Geest, John A Blessing, Robert T Morris, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2001
Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancerJ B Welsh, P P Zarrinkar, L M Sapinoso, et al.
Pageof 74

Showing results (291-300 of 738) with videos related to

Sort By:
Pageof 74
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancerGiorgio Bogani, Robert L Coleman, Ignace Vergote, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2008
Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success?John K Chan, Stefanie M Ueda, Valerie E Sugiyama, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 15, 2023
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancerGiorgio Bogani, Robert L Coleman, Ignace Vergote, et al.
Obstetrics and Gynecology|December 7, 2002
A stiff bristled, spiral-shaped ectocervical brush: a device for transepithelial tissue biopsyBradley J Monk, Michael Cogan, Juan C Felix, et al.
Journal of Pain and Symptom Management|May 18, 2010
A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group studyVivian E von Gruenigen, Helen Q Huang, Karen M Gil, et al.
Gynecologic Oncology|December 14, 2004
Role of pegylated liposomal doxorubicin in ovarian cancerJ Tate Thigpen, Carol A Aghajanian, David S Alberts, et al.
Gynecologic Oncology|October 13, 2018
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group studyBradley J Monk, James T Kauderer, Katherine M Moxley, et al.
Gynecologic Oncology|December 27, 2008
Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group studyLeslie M Randall, Bradley J Monk, Kathleen M Darcy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group studyKoen De Geest, John A Blessing, Robert T Morris, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2001
Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancerJ B Welsh, P P Zarrinkar, L M Sapinoso, et al.
Pageof 74